"With up to 60 per cent of dogs in the UK estimated to be overweight or obese, the market for such drugs could be considerable."
"Okava, a San Francisco-based bio-pharma company which specializes in pet health, is planning to run trials for a drug designed to mimic the effects of Ozempic."
"The current market for such a product could be worth $10bn, and they hope to have a canine weight-loss drug available as early as 2028 or 2029."
"Both human weight-loss drugs, Mounjaro and Ozempic, mimic a natural hormone called GLP-1, which regulates blood sugar and appetite."
The obesity epidemic in dogs has led to the exploration of weight-loss drugs specifically for pets. Up to 60% of dogs in the UK are estimated to be overweight or obese, creating a considerable market for such solutions. Okava, a biotech firm, is initiating trials for a drug mimicking the effects of popular human weight-loss drugs such as Ozempic, aiming for an implant version for dogs. Analysts predict a $10 billion market, with products potentially available by 2028 or 2029.
Read at www.independent.co.uk
Unable to calculate read time
Collection
[
|
...
]